{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T10:15:46Z","timestamp":1742638546725,"version":"3.37.3"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014305","name":"HIV Research Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014305","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.diagmicrobio.2016.08.004","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T20:26:55Z","timestamp":1470774415000},"page":"289-292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["In vitro antifungal susceptibility profiles of Cryptococcus species isolated from HIV-associated cryptococcal meningitis patients in Zimbabwe"],"prefix":"10.1016","volume":"86","author":[{"given":"Tinashe K.","family":"Nyazika","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia F.","family":"Herkert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferry","family":"Hagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kudzanai","family":"Mateveke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie J.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques F.","family":"Meis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0005","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/myc.12171","article-title":"Molecular epidemiology and antifungal susceptibility of Serbian Cryptococcus neoformans isolates","volume":"57","author":"Arsic Arsenijevic","year":"2014","journal-title":"Mycoses"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0010","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMoa1509024","article-title":"Adjunctive dexamethasone in HIV-associated cryptococcal meningitis","volume":"374","author":"Beardsley","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0015","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/1469-0691.12019","article-title":"Genotyping and antifungal susceptibility testing of Cryptococcus neoformans isolates from Cameroonian HIV-positive adult patients","volume":"19","author":"Bertout","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0020","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1473-3099(05)70197-3","article-title":"Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis","volume":"5","author":"Bicanic","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1086\/588792","article-title":"High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial","volume":"47","author":"Bicanic","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0030","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.diagmicrobio.2016.02.009","article-title":"Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013)","volume":"85","author":"Castanheira","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0035","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/13693786.2012.715763","article-title":"Fluconazole resistance in cryptococcal disease: emerging or intrinsic?","volume":"51","author":"Cheong","year":"2013","journal-title":"Med Mycol"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0040","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1099\/jmm.0.029025-0","article-title":"In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformansVar. grubii and Cryptococcus gattii serotype B from north-western India","volume":"60","author":"Chowdhary","year":"2011","journal-title":"J Med Microbiol"},{"year":"2008","series-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A3","author":"Clinical and Laboratory Standards Institute","key":"10.1016\/j.diagmicrobio.2016.08.004_bb0045"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/675213","article-title":"Global molecular epidemiology of Cryptococcus neoformans and Cryptococcus gattii: an atlas of the molecular types","author":"Cogliati","year":"2013","journal-title":"Scientifica"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0055","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1474-7766.2004.00254.x","article-title":"Cryptococcal meningitis","volume":"4","author":"Day","year":"2004","journal-title":"Pract Neurol"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0060","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1056\/NEJMoa1110404","article-title":"Combination antifungal therapy for cryptococcal meningitis","volume":"368","author":"Day","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0065","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1128\/AAC.01115-12","article-title":"Cryptococcus neoformans\u2013Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole","volume":"56","author":"Espinel-Ingroff","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0070","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1128\/AAC.06252-11","article-title":"Cryptococcus neoformans\u2013Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine","volume":"56","author":"Espinel-Ingroff","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0075","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1128\/AAC.04055-14","article-title":"Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans\u2013Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method","volume":"59","author":"Espinel-Ingroff","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0080","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1128\/AAC.00746-10","article-title":"In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates","volume":"54","author":"Hagen","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0085","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1128\/JCM.06750-11","article-title":"Extensive genetic diversity within the Dutch clinical Cryptococcus neoformans population","volume":"50","author":"Hagen","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0090","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.fgb.2015.02.009","article-title":"Recognition of seven species in the Cryptococcus gattii\/Cryptococcus neoformans species complex","volume":"78","author":"Hagen","year":"2015","journal-title":"Fungal Genet Biol"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0095","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1128\/AAC.01384-07","article-title":"In vitroactivity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba","volume":"52","author":"Illnait-Zaragozi","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0100","first-page":"60","article-title":"Susceptibility of Cryptococcus neoformans and Cryptococcus gattii from clinical and environment sources in Nairobi, Kenya","volume":"92","author":"Kangogo","year":"2015","journal-title":"East Afr Med J"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/mmy.40.1.7.11","article-title":"Cryptococcal meningitis caused by Cryptococcus neoformans var. gattii, serotype C, in AIDS patients in Soweto, South Africa","volume":"40","author":"Karstaedt","year":"2002","journal-title":"Med Mycol"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0110","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ijantimicag.2008.11.007","article-title":"Cryptococcus neoformans serotype A and Cryptococcus gattii serotype B isolates differ in their susceptibilities to fluconazole and voriconazole","volume":"33","author":"Khan","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0115","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1086\/432486","article-title":"Prevalence of clinical isolates of Cryptococcus gattii serotype C among patients with AIDS in sub-Saharan Africa","volume":"192","author":"Litvintseva","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0120","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.diagmicrobio.2012.02.018","article-title":"Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility","volume":"73","author":"Lockhart","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0125","series-title":"Advances in applied microbiology","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0065-2164(08)01005-8","article-title":"Virulence in Cryptococcus species","author":"Ma","year":"2009"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0130","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrmicro.2015.6","article-title":"Cryptococcus: from environmental saprophyte to global pathogen","volume":"14","author":"May","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0135","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1097\/QAD.0b013e3280106d6a","article-title":"Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence","volume":"20","author":"McCarthy","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0140","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1111\/j.1439-0507.2010.01946.x","article-title":"Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates from AIDS patients in Kenya","volume":"54","author":"Mdodo","year":"2011","journal-title":"Mycoses"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0145","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1086\/649861","article-title":"Combination flucytosine and high dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi","volume":"50","author":"Nussbaum","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0150","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jinf.2016.02.018","article-title":"Cryptococcus tetragattii as a major cause of cryptococcal meningitis among HIV-infected individuals in Harare, Zimbabwe","volume":"72","author":"Nyazika","year":"2016","journal-title":"J Infect"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0155","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0000000000001212","article-title":"Cryptococcal meningitis presenting as a complication in HIV-infected children: a case series from sub-Saharan Africa","author":"Nyazika","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0160","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/myc.12444","article-title":"Comparison of biotyping methods as alternative identification tools to molecular typing of pathogenic Cryptococcus species in sub-Saharan Africa","volume":"59","author":"Nyazika","year":"2016","journal-title":"Mycoses"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0165","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/QAD.0b013e328322ffac","article-title":"Estimation of the current global burden of cryptococcal meningitis among persons living with HIV\/AIDS","volume":"23","author":"Park","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0170","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0175","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/ja.2015.29","article-title":"Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010\u20132012)","volume":"68","author":"Pfaller","year":"2015","journal-title":"J Antibiot"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0180","first-page":"71","article-title":"Cryptococcus gattii: a dilemma in diagnosis and treatment in sub-Saharan Africa an area with high HIV prevalence","volume":"59","author":"Robertson","year":"2013","journal-title":"Cent Afr J Med"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0185","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1086\/313757","article-title":"Practice guidelines for the management of cryptococcal disease","volume":"30","author":"Saag","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0190","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3109\/13693781003774689","article-title":"In-hospital mortality of HIV-infected cryptococcal meningitis patients with C. gattii and C. neoformans infection in Gaborone, Botswana","volume":"48","author":"Steele","year":"2010","journal-title":"Med Mycol"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0195","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.01216-08","article-title":"Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans","volume":"53","author":"Thompson","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.08.004_bb0200","first-page":"119","article-title":"Antifungal drug resistance in pathogenic fungi","volume":"36","author":"Vanden Bossche","year":"1998","journal-title":"Med Mycol"},{"year":"2011","series-title":"Rapid advice diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children","author":"World Health Organization (WHO)","key":"10.1016\/j.diagmicrobio.2016.08.004_bb0205"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889316302413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889316302413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T20:01:22Z","timestamp":1718740882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889316302413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0732889316302413"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2016.08.004","relation":{},"ISSN":["0732-8893"],"issn-type":[{"type":"print","value":"0732-8893"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro antifungal susceptibility profiles of Cryptococcus species isolated from HIV-associated cryptococcal meningitis patients in Zimbabwe","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2016.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}